123 related articles for article (PubMed ID: 38128180)
1. Integrated transcriptomic and proteomic analysis reveals Guizhi-Fuling Wan inhibiting STAT3-EMT in ovarian cancer progression.
Ma Q; Chen F; Liu Y; Wu K; Bu Z; Qiu C; Neamati N; Lu T
Biomed Pharmacother; 2024 Jan; 170():116016. PubMed ID: 38128180
[TBL] [Abstract][Full Text] [Related]
2. Guizhi Fuling capsule relieves memory deficits by inhibition of microglial neuroinflammation through blocking JAK2/STAT3 pathway in presenilin1/2 conditional double knockout mice.
Yang G; Tong Y; Wang X; Zhao C; Ba Z; Ahelijiang R; Liu X; Gao W; Zhao Y; Gu Y; Yang J; Xu Y
Front Immunol; 2023; 14():1185570. PubMed ID: 37465679
[TBL] [Abstract][Full Text] [Related]
3. Protective mechanism of traditional Chinese medicine guizhi fuling pills against carbon tetrachloride-induced kidney damage is through inhibiting oxidative stress, inflammation and regulating the intestinal flora.
Xu B; Zheng J; Tian X; Yuan F; Liu Z; Zhou Y; Yang Z; Ding X
Phytomedicine; 2022 Jul; 101():154129. PubMed ID: 35490491
[TBL] [Abstract][Full Text] [Related]
4. Guizhi fuling capsule, an ancient Chinese formula, attenuates endometriosis in rats via induction of apoptosis.
Hu C; Wang Z; Pang Z; Lu W; Cai X; Yang J; Wang D; Cao P
Climacteric; 2014 Aug; 17(4):410-6. PubMed ID: 24559203
[TBL] [Abstract][Full Text] [Related]
5. Systemic pharmacological verification of Guizhi Fuling decoction in treating endometriosis-associated pain.
Gao Y; Ji W; Lu M; Wang Z; Jia X; Wang D; Cao P; Hu C; Sun X; Wang Z
J Ethnopharmacol; 2022 Oct; 297():115540. PubMed ID: 35870685
[TBL] [Abstract][Full Text] [Related]
6. Guizhi Fuling pill attenuates liver fibrosis
Liu Z; Xu B; Ding Y; Ding X; Yang Z
Bioengineered; 2022 Apr; 13(4):9357-9368. PubMed ID: 35387552
[TBL] [Abstract][Full Text] [Related]
7. Multi-omics profiling reveals key signaling pathways in ovarian cancer controlled by STAT3.
Lu T; Bankhead A; Ljungman M; Neamati N
Theranostics; 2019; 9(19):5478-5496. PubMed ID: 31534498
[TBL] [Abstract][Full Text] [Related]
8. The anti-tumor effect of OP-B on ovarian cancer in vitro and in vivo, and its mechanism: An investigation using network pharmacology-based analysis.
Yuan S; Xu Y; Yi T; Wang H
J Ethnopharmacol; 2022 Jan; 283():114706. PubMed ID: 34614446
[TBL] [Abstract][Full Text] [Related]
9. Integrated Metabolomics and Network Pharmacology to Reveal the Mechanisms of Guizhi-Fuling Treatment for Myocardial Ischemia.
Duan B; Ye Y; Zhou Z; Han L; Huang F; Li J; Wang Q; Zeng X; Yu X
Chem Biodivers; 2022 Oct; 19(10):e202200386. PubMed ID: 36073658
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of PADI2 prevents proliferation and epithelial-mesenchymal transition in ovarian cancer through inhibiting JAK2/STAT3 pathway in vitro and in vivo, alone or in combination with Olaparib.
Liu L; Zhang Z; Zhang G; Wang T; Ma Y; Guo W
J Transl Med; 2020 Sep; 18(1):357. PubMed ID: 32951601
[TBL] [Abstract][Full Text] [Related]
11. Ginkgetin suppresses ovarian cancer growth through inhibition of JAK2/STAT3 and MAPKs signaling pathways.
Wu L; Qian C; Zhang W; Shi M; Chen X; Wang Y; Lin F
Phytomedicine; 2023 Jul; 116():154846. PubMed ID: 37172479
[TBL] [Abstract][Full Text] [Related]
12. Novel role of lncRNA CHRF in cisplatin resistance of ovarian cancer is mediated by miR-10b induced EMT and STAT3 signaling.
Tan WX; Sun G; Shangguan MY; Gui Z; Bao Y; Li YF; Jia ZH
Sci Rep; 2020 Sep; 10(1):14768. PubMed ID: 32901049
[TBL] [Abstract][Full Text] [Related]
13. Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer.
Wen W; Liang W; Wu J; Kowolik CM; Buettner R; Scuto A; Hsieh MY; Hong H; Brown CE; Forman SJ; Horne D; Morgan R; Wakabayashi M; Dellinger TH; Han ES; Yim JH; Jove R
Mol Cancer Ther; 2014 Dec; 13(12):3037-48. PubMed ID: 25319391
[TBL] [Abstract][Full Text] [Related]
14. Serotonin/HTR1E signaling blocks chronic stress-promoted progression of ovarian cancer.
Qin X; Li J; Wang S; Lv J; Luan F; Liu Y; Chen Y; Chen X; Zhao Y; Zhu J; Piao Y; Zhang W; Shi Y; Xiang R; Qu P; Wang L
Theranostics; 2021; 11(14):6950-6965. PubMed ID: 34093864
[No Abstract] [Full Text] [Related]
15. L1CAM promotes ovarian cancer stemness and tumor initiation via FGFR1/SRC/STAT3 signaling.
Giordano M; Decio A; Battistini C; Baronio M; Bianchi F; Villa A; Bertalot G; Freddi S; Lupia M; Jodice MG; Ubezio P; Colombo N; Giavazzi R; Cavallaro U
J Exp Clin Cancer Res; 2021 Oct; 40(1):319. PubMed ID: 34645505
[TBL] [Abstract][Full Text] [Related]
16. MiR-3666 serves as a tumor suppressor in ovarian carcinoma by down-regulating AK4 via targeting STAT3.
Tan H; Wu C; Huang B; Jin L; Jiang X
Cancer Biomark; 2021; 30(4):355-363. PubMed ID: 33361582
[TBL] [Abstract][Full Text] [Related]
17. Add-on effect of the Guizhi Fuling formula for management of reduced fertility potential in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials.
Rong A; Ta N; E L; Meng W
Front Endocrinol (Lausanne); 2022; 13():995106. PubMed ID: 37143960
[TBL] [Abstract][Full Text] [Related]
18. A Chinese classical prescription Guizhi-Fuling Wan in treatment of ovarian cancer: An overview.
Wang X; Su P; Hao Q; Zhang X; Xia L; Zhang Y
Biomed Pharmacother; 2022 Sep; 153():113401. PubMed ID: 36076526
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of Chinese herbal medicine Guizhi Fuling capsule combined with low dose mifepristone in the treatment of uterine fibroids: a systematic review and meta-analysis of 28 randomized controlled trials.
Lei Y; Yang L; Yang H; Li M; Ou L; Bai Y; Dong T; Gao F; Wei P
BMC Complement Med Ther; 2023 Feb; 23(1):54. PubMed ID: 36803997
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics-derived absorbed components responsible for Guizhi-Fuling capsule target PI3K/Akt-Erk to exert an anti-dysmenorrhea effect.
Zhao Q; Cheng J; Bian X; Wang C; Xu Y; Ding H; Ren H; Zhang Y; Xu M; Shan C; Yan H; Duan J; Qian D; Huang X
J Ethnopharmacol; 2022 Oct; 297():115525. PubMed ID: 35811027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
